产品名称

NVP-ACC789 - ACC789 | ZK 202650

产品货号

Axon 2865 CAS [300842-64-2] MF C21H17BrN4MW 405.29 Purity: 99% Soluble in DMSO Description NVP-ACC789 is a VEGFR2 inhibitor (IC50 value of 0.02 µM) moderately active against VEGFR1 and VEGFR3, but has little activity against PDGFR-β tyrosine kinases. Blocks angiogenesis induced by VEGF in vivo and in vitro. KEYWORDS: NVP-ACC789 | supplier | VEGFR2 inhibitor | ACC789 | ZK 202650 | ACC-789 | ACC 789 | ZK-202650 | ZK202650 | CAS [300842-64-2] | VEGF | VEGFR | Inhibitor | Receptors | Angiogenesis

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

NVP-ACC789 - ACC789 | ZK 202650

Based on 2 reference(s) in Google Scholar 8 10 2

Axon 2865

CAS [300842-64-2]

MF C21H17BrN4
MW 405.29

Purity: 99%
Soluble in DMSO

NVP-ACC789

Description

NVP-ACC789 is a VEGFR2 inhibitor (IC50 value of 0.02 µM) moderately active against VEGFR1 and VEGFR3, but has little activity against PDGFR-β tyrosine kinases. Blocks angiogenesis induced by VEGF in vivo and in vitro.

KEYWORDS: NVP-ACC789 | supplier | VEGFR2 inhibitor | ACC789 | ZK 202650 | ACC-789 | ACC 789 | ZK-202650 | ZK202650 | CAS [300842-64-2] | VEGF | VEGFR | Inhibitor | Receptors | Angiogenesis

JC Tille et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther. 2001 Dec;299(3):1073-85.

Angiogenesis Cell Signaling & Oncology VEGFR RTK class IV; EC 2.7.10.1

Inhibitor of VEGFR2

Chemical name

N-(3-Bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine

Parent CAS No.

[300842-64-2]

产品资料